| abstract |
Piperidine compounds having the general general Formula Iwherein R<sup>1</sup> isa group having the general Formula II :wherein X is CHR<sup>10</sup>, O, S, SO, SO<sub>2</sub> or NR<sup>10</sup>, R<sup>10</sup> being hydrogen, alkyl or alkenyl, an amino group, sulfonyl, optionally substituted phenyl or a hetero aromatic group; Y is CH, CH<sub>2</sub>, NH, C=O or C=S; R<sup>a</sup> ― R<sup>d</sup> are substituents; U is CH<sub>2</sub>, O or S; Q<sup>1</sup> is a bond , alkylene or alkenylen and Q<sup>2</sup> alkylene having at least two C-atoms or alkenyleneR<sup>2</sup> and R<sup>3</sup> are hydrogen, or alkyl or they may together form an ethylene or propylene bridge; R<sup>4</sup> to R<sup>7</sup> are substituents; andZ<sup>1</sup> is substituent, Z<sup>2</sup> is hydrogen and Z<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub> wherein n is 0; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease. |